ArticleDrugs2011

Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.

Philip J Saylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.